These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22673852)

  • 1. The practical detection of mmp-9 diagnoses ocular surface disease and may help prevent its complications.
    Kaufman HE
    Cornea; 2013 Feb; 32(2):211-6. PubMed ID: 22673852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye.
    Sambursky R; Davitt WF; Latkany R; Tauber S; Starr C; Friedberg M; Dirks MS; McDonald M
    JAMA Ophthalmol; 2013 Jan; 131(1):24-8. PubMed ID: 23307206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunoassay for matrix metalloproteinase-9 in the tear film of patients with pseudoexfoliation syndrome - a pilot study].
    Zimmermann N; Erb C
    Klin Monbl Augenheilkd; 2013 Aug; 230(8):804-7. PubMed ID: 23670526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective, multicenter, clinical evaluation of point-of-care matrix metalloproteinase-9 test for confirming dry eye disease.
    Sambursky R; Davitt WF; Friedberg M; Tauber S
    Cornea; 2014 Aug; 33(8):812-8. PubMed ID: 24977985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface.
    Luo L; Li DQ; Doshi A; Farley W; Corrales RM; Pflugfelder SC
    Invest Ophthalmol Vis Sci; 2004 Dec; 45(12):4293-301. PubMed ID: 15557435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory markers in the tears of patients with ocular surface disease.
    Acera A; Rocha G; Vecino E; Lema I; Durán JA
    Ophthalmic Res; 2008 Oct; 40(6):315-21. PubMed ID: 18688174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
    Toker E; Asfuroğlu E
    Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic effect of DA-6034 on ocular inflammation via suppression of MMP-9 and inflammatory cytokines and activation of the MAPK signaling pathway in an experimental dry eye model.
    Seo MJ; Kim JM; Lee MJ; Sohn YS; Kang KK; Yoo M
    Curr Eye Res; 2010 Feb; 35(2):165-75. PubMed ID: 20136427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allergic complications with laser-assisted in-situ keratomileusis.
    Bielory BP; O'Brien TP
    Curr Opin Allergy Clin Immunol; 2011 Oct; 11(5):483-91. PubMed ID: 21822133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MMP-9 and the perioperative management of LASIK surgery.
    Sambursky R; O'Brien TP
    Curr Opin Ophthalmol; 2011 Jul; 22(4):294-303. PubMed ID: 21537181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dry Eye Profiles in Patients with a Positive Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test Versus Negative Patients.
    Lanza NL; McClellan AL; Batawi H; Felix ER; Sarantopoulos KD; Levitt RC; Galor A
    Ocul Surf; 2016 Apr; 14(2):216-23. PubMed ID: 26807724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Matrix Metalloproteinase 9 Point-of-Care Test in Dry Eye.
    Lanza NL; Valenzuela F; Perez VL; Galor A
    Ocul Surf; 2016 Apr; 14(2):189-95. PubMed ID: 26850527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [What's new in ocular surface disease?].
    Messmer EM; Benitez-Del-Castillo JM; Lambiase A; Doan S
    Ophthalmologe; 2005 Mar; 102(3):293-300. PubMed ID: 15616816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dry eye syndrome and allergic conjunctivitis--epidemics of XXI century--diagnostic problems and management].
    Kubicka-Trzaska A; Romanowska-Dixon B
    Przegl Lek; 2009; 66(11):967-71. PubMed ID: 20297640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye.
    Pflugfelder SC; Farley W; Luo L; Chen LZ; de Paiva CS; Olmos LC; Li DQ; Fini ME
    Am J Pathol; 2005 Jan; 166(1):61-71. PubMed ID: 15632000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy, Dry Eye, and Ocular Surface Diseases.
    Sosne G; Rimmer D; Kleinman HK; Ousler G
    Vitam Horm; 2016; 102():277-306. PubMed ID: 27450739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye.
    De Paiva CS; Corrales RM; Villarreal AL; Farley WJ; Li DQ; Stern ME; Pflugfelder SC
    Exp Eye Res; 2006 Sep; 83(3):526-35. PubMed ID: 16643899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
    Salib GM; McDonald MB; Smolek M
    J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postrefractive surgery dry eye.
    Quinto GG; Camacho W; Behrens A
    Curr Opin Ophthalmol; 2008 Jul; 19(4):335-41. PubMed ID: 18545018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the Matrix Metalloproteinase 9 Point-of-Care Test Positivity According to MMP-9 Concentration and Loading Volume.
    Huh J; Choi SY; Eom Y; Kim HM; Song JS
    Cornea; 2020 Feb; 39(2):234-236. PubMed ID: 31369458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.